Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214228 | 0.69 | GSK3B (0.64) | RAB9AMEN1KMT2AMAPTLMNA | |
| SCHEMBL17187853 | 0.69 | GSK3B (0.64) | RAB9AMEN1KMT2AMAPTLMNA | |
| SCHEMBL196299 | 0.69 | GSK3B (0.64) | RAB9AMEN1KMT2AMAPTLMNA | |
| SCHEMBL12220178 | 0.68 | GSK3B (0.52) | RAB9ACXCR3MEN1KMT2AMAPT | |
| SCHEMBL14373587 | 0.68 | CXCR3 (1.00) | RAB9ACXCR3MEN1KMT2AMAPT | |
| SCHEMBL11530650 | 0.68 | KDR (0.53) | RAB9ACXCR3MEN1KMT2AMAPT | |
| SCHEMBL15340905 | 0.67 | KMT2A (0.64) | RAB9AMEN1KMT2AMAPTLMNA | |
| Bromide SCHEMBL2532767 | 0.67 | RAB9A (0.51) | RAB9ACXCR3MEN1KMT2AMAPT | |
| SCHEMBL318783 | 0.66 | HSD17B3 (0.67) | RAB9AMEN1KMT2AMAPTLMNA | |
| SCHEMBL10551432 | 0.66 | ALDH1A1 (0.58) | RAB9AMEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240151993-A1 | ELECTRON WITHDRAWING GROUP (EWG)-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS | META PLATFORMS TECHNOLOGIES, LLC | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240151993-A1 | ELECTRON WITHDRAWING GROUP (EWG)-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS | AR, OR10J3, ESRRG | RAB9A 2182/4885CXCR3 1345/4885MEN1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.